Results 301 to 310 of about 3,384,149 (326)

Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections

Current Opinion in Infectious Diseases, 2018
Purpose of review In the absence of randomized clinical trial data, questions remain regarding the optimal treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections. CRE have historically been susceptible to polymyxins, tigecycline or aminoglycosides (mostly gentamicin), and these antibiotics have long been ...
Tumbarello M., Losito A. R., Giamarellou H.   +2 more
openaire   +3 more sources

Treatment of infections caused by carbapenemase-producing Enterobacteriaceae

Enfermedades Infecciosas y Microbiología Clínica, 2014
Treatment of infections caused by carbapenemase-producing Enterobacteriaceae (CPE) is currently one of the most important challenges of infectious diseases. The available information is based on in vitro studies, some animal model data and a few case studies and retrospective cohorts; appropriate data are lacking or are very scarce for some old ...
Jesús Rodríguez-Baño, José Antonio Martínez, José Miguel Cisneros, Carlota Gudiol   +3 more
openaire   +3 more sources

Ceftazidime therapy of infections caused by Enterobacteriaceae and Pseudomonas aeruginosa [PDF]

Journal of Antimicrobial Chemotherapy, 1983
Sixteen patients with serious Gram-negative bacillary infections were treated with intravenous ceftazidime, 2 g every 8 h. The majority of patients had bacteraemia or pneumonitis or both. Ten patients were cured and six improved. Seven of ten patients infected with Pseudomonas aeruginosa were cured, and three improved.
Robert Press, Michael S. Simberkoff, Alan A. Pollock, Wafaa El-Sadr, Melanie J. Maslow, James J. Rahal, Alma S. Richmond, Amy Rosenberg, David Silverman   +8 more
openaire   +2 more sources

Risk of resistant infections with Enterobacteriaceae in hospitalized neonates

The Pediatric Infectious Disease Journal, 2002
To determine the risk factors associated with progression from colonization to infection with health care-associated antimicrobial-nonsusceptible Enterobacteriaceae (ANE) in critically ill neonates.During a 3-year period (1998 to 2000), surveillance rectal cultures were performed on neonates admitted to our Level III neonatal intensive care unit after ...
Nalini Singh, Bruce M. Sprague, Kantilal M. Patel, Joseph M. Campos, Nnenna Kalu, Billie L. Short, Marie-Michèle Leger   +6 more
openaire   +3 more sources

Health outcomes attributable to carbapenemase-producing Enterobacteriaceae infections: A systematic review and meta-analysis

Infection control and hospital epidemiology, 2019
Background: Carbapenemase-producing Enterobacteriaceae (CPE) pose a significant global health threat. Objective: To conduct a systematic review of health outcomes and long-term sequelae attributable to CPE infection. Methods: We followed PRISMA reporting
Dalton R. Budhram, S. Mac, J. Bielecki, Samir N. Patel, B. Sander   +4 more
semanticscholar   +1 more source

Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae

Current Treatment Options in Infectious Diseases, 2014
Treatment of infections by carbapenem-resistant enterobacteriaceae (CRE) is challenging because of the limited choice of active antibiotics and the scarcity of good data supporting any treatment regimen. Currently, there are no randomized controlled trials on the treatment of CRE infections and all data have been obtained from case report and ...
Stephan Göttig, Axel Hamprecht
openaire   +2 more sources

ESBL-producing Enterobacteriaceae: controlling the spread of infection

British Journal of Nursing, 2007
Extended spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae were first reported in Europe in the 1980s and have since become a worldwide problem. This has resulted in increased morbidity, mortality and cost in treating the infections they cause (Paterson et al, 2001; Bisson et al, 2002). In the UK the prevalence of ESBL rose from 5.4% in 1997 to
openaire   +3 more sources

Disparity in infection control practices for multidrug-resistant Enterobacteriaceae

American Journal of Infection Control, 2012
There is a lack of empiric evidence regarding the optimal approach to controlling the transmission of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) and carbapenem-resistant Enterobacteriaceae (CRE). In this context, we expect that infection control practices for these organisms vary widely between hospitals.A survey examining ...
Kevin Katz, Kevin Katz, Allison McGeer, Allison McGeer, Christopher F. Lowe, Matthew P. Muller, Matthew P. Muller   +6 more
openaire   +3 more sources

The Role of Vaginal Colonization with Enterobacteriaceae in Recurrent Urinary Infections

Journal of Urology, 1975
Quantitative cultures of the vaginal introitus for Enterobacteriaceae, S. faecalis and P. aeruginosa were compared in 20 premenopausal normal women (200 cultures) to 198 consecutive cultures from 9 premenopausal women in between episodes of bacteriuria. Introital colonization in patients susceptible to urinary infections was significantly higher for E.
Thomas A. Stamey, Carlton C. Sexton
openaire   +3 more sources

Challenges in the Management of Infections due to Carbapenem-Resistant Enterobacteriaceae

Infection Control & Hospital Epidemiology, 2014
Carbapenem-resistant Enterobacteriaceae (CRE) infections are increasing and are associated with considerable morbidity and mortality. Members of the Emerging Infections Network treating CRE encountered difficulties in obtaining laboratory results and struggled with limited treatment options.
Sean Elliott, Scott J. Weissman, Susan E. Beekmann, Deepa Mukundan, Philip M. Polgreen, Marnie Rosenthal, Dimitri Drekonja, Dimitri Drekonja, Pranita D. Tamma, Hari Polenakovik   +9 more
openaire   +3 more sources